CN114717169B - 一种瑞士乳杆菌及其在制备调节生殖道微生态和缓解生殖道干涩产品中的应用 - Google Patents
一种瑞士乳杆菌及其在制备调节生殖道微生态和缓解生殖道干涩产品中的应用 Download PDFInfo
- Publication number
- CN114717169B CN114717169B CN202210649748.9A CN202210649748A CN114717169B CN 114717169 B CN114717169 B CN 114717169B CN 202210649748 A CN202210649748 A CN 202210649748A CN 114717169 B CN114717169 B CN 114717169B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus helveticus
- genital tract
- vaginal
- eha08
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000002605 Lactobacillus helveticus Species 0.000 title claims abstract description 49
- 235000013967 Lactobacillus helveticus Nutrition 0.000 title claims abstract description 47
- 229940054346 lactobacillus helveticus Drugs 0.000 title claims abstract description 47
- 210000005000 reproductive tract Anatomy 0.000 title abstract description 38
- 230000001105 regulatory effect Effects 0.000 title abstract description 9
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims abstract description 12
- 238000004321 preservation Methods 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 10
- 201000008100 Vaginitis Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 208000032159 Vaginal inflammation Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229940011871 estrogen Drugs 0.000 claims description 3
- 239000000262 estrogen Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 210000001215 vagina Anatomy 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 210000004877 mucosa Anatomy 0.000 abstract description 7
- 230000007794 irritation Effects 0.000 abstract description 2
- 238000000855 fermentation Methods 0.000 description 26
- 230000004151 fermentation Effects 0.000 description 26
- 230000001580 bacterial effect Effects 0.000 description 20
- 239000000843 powder Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 239000001963 growth medium Substances 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 11
- 241000186660 Lactobacillus Species 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 229940039696 lactobacillus Drugs 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000003385 bacteriostatic effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 5
- 229960000282 metronidazole Drugs 0.000 description 5
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000009608 Papillomavirus Infections Diseases 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 210000004392 genitalia Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000010802 sludge Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 206010046914 Vaginal infection Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000605059 Bacteroidetes Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 206010058821 Genital tract inflammation Diseases 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 206010001526 Air embolism Diseases 0.000 description 1
- 241001135756 Alphaproteobacteria Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000131694 Tenericutes Species 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009655 industrial fermentation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Wood Science & Technology (AREA)
- Nutrition Science (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种瑞士乳杆菌及其在制备调节生殖道微生态和缓解生殖道干涩产品中的应用。所述瑞士乳杆菌EHA08,经鉴定为瑞士乳杆菌(Lactobacillus helveticus),菌株名为EHA08,保藏于中国典型培养物保藏中心,保藏日期为2020年10月19日,保藏编号为CCTCC NO:M20200598。本发明提供的瑞士乳杆菌EHA08对阴道粘膜无刺激性,可以作为直接用于阴道微生态干预的生物制剂,能够大幅改善生殖道菌群结构,有效治疗妇科炎症;并且对妇科炎症干预治疗后,能有效防止复发。此外,本发明瑞士乳杆菌EHA08,能够有效缓解中老年女性阴道干涩,效果显著。
Description
技术领域
本发明属于微生物技术领域,具体涉及一种瑞士乳杆菌及其在制备调节生殖道微生态和缓解生殖道干涩产品中的应用。
背景技术
妇女正常的阴道微生态是其生殖健康的重要指标,多种因素可影响阴道微生态的平衡,继之引起阴道内源性和外源性微生物入侵而发生各种阴道炎症,重者引起子宫内膜炎症至盆腔炎性疾病,并可造成不良妊娠结局及不孕,从而严重影响患者的工作与生活质量。临床上常见的许多妇科感染性疾患都存在明显的阴道微生态系统失衡,了解并关注阴道微生态环境的平衡,对生殖道感染性疾病的治疗有重大意义,治疗理念已从以往杀灭微生物转变到增加益生菌、恢复阴道正常微生态环境,进而提高治愈率,减少复发和再感染率。
阴道炎主要治疗手段是阴道用药。资料显示,37%~66%的患者均常规阴道冲洗,而阴道冲洗易破坏阴道生态环境,并可能引起上行性感染,增加盆腔感染性疾病的发生,间接影响输卵管功能,破坏输卵管纤毛上皮等,故不提倡。
有研究显示,细菌性阴道炎临床治愈率达90% 左右,但容易在3个月内复发,而阴道炎的反复发作,重复使用抗菌药物,导致抗菌药耐药性增强,直接影响着患者的治愈情况,使得治愈率越来越低,疾病的复发率也在逐年升高。
抗生素干预依然是各种生殖道感染的治疗策略,这不仅无法复原生殖道内正常菌群区系,还会导致更严重的反复感染(30-40%复发率)。研究发现,由阴道内分离的菌株治疗细菌性阴道炎等生殖道感染的治愈率约为88-96%,远高于抗生素治疗(77%),同时复发率低。
除选用病原体敏感、疗效高的药物外,通过采用调整微生态的制剂,扶正和保护阴道正常菌群的组成和比例,恢复其自然的防御能力,促进自净作用,是今后生殖道感染治疗研究的必然趋势。健康妇女阴道乳杆菌的数量占阴道微生物的 95%以上,是健康育龄女性正常菌群中的优势菌,优势菌是决定一个微生物群生态平衡的核心。
如何有效恢复健康生殖道菌群是预防妇科疾病发生的关键。
发明内容
发明目的:针对现有技术存在的问题,本发明目的是提供了一种瑞士乳杆菌及其在制备调节生殖道微生态和缓解生殖道干涩产品中的应用。
技术方案:为了达到上述发明目的,本发明所采用的技术方案如下:
一种瑞士乳杆菌,经鉴定为瑞士乳杆菌(Lactobacillus helveticus),菌株名为EHA08,保藏于中国典型培养物保藏中心,保藏日期为2020年10月19日,保藏编号为CCTCCNO:M2020598。
本发明还提供了上述瑞士乳杆菌在制备产品中的应用,所述产品用于调节生殖道微生态和/或缓解生殖道干涩。
进一步的,所述调节生殖道微生态包括:抑制或杀灭致病菌、恢复pH值生态环境指标和/或增加健康菌群比例;所述生殖道干涩为雌激素水平下降所引起的生殖道干涩。
进一步的,所述产品用于治疗生殖道炎症和/或缓解生殖道干涩。
作为具体实施方案,所述产品为食品、药物或保健食品。
优选的,所述药物的剂型为粉剂、颗粒剂、胶囊剂、片剂、丸剂或口服液;所述食品为保健食品;或者所述食品包括乳制品、豆制品、肉制品或果蔬制品;或者所述食品为饮料或零食。
本发明还提供了一种组合物,所述组合物包含上述的瑞士乳杆菌。
进一步的,所述组合物包含所述的瑞士乳杆菌、药物载体和/或药用辅料。
优选的,所述药物载体包含微囊、微球、纳米粒和/或脂质体;所述药用辅料包含赋形剂和/或附加剂。更优选的,所述赋形剂包含黏合剂、填充剂、崩解剂和/或润滑剂;所述附加剂包含增溶剂、助溶剂、潜溶剂和/或防腐剂。
进一步的,所述组合物包含所述的瑞士乳杆菌和食用辅料。
本发明最后提供了所述的组合物在制备产品中的应用,所述产品用于调节生殖道微生态和/或缓解生殖道干涩。
进一步的,所述产品用于治疗生殖道炎症和/或缓解生殖道干涩。
有益效果:与现有技术相比,本发明提供的瑞士乳杆菌EHA08对阴道粘膜无刺激性,可以作为直接用于阴道微生态干预的生物制剂。实验结果表明,本发明瑞士乳杆菌EHA08,能够大幅改善生殖道菌群结构,有效治疗妇科炎症;并且对妇科炎症干预治疗后,能有效防止复发。此外,本发明瑞士乳杆菌EHA08,能够有效缓解中老年女性阴道干涩,效果显著。
附图说明
图1为瑞士乳杆菌EHA08生物进化树。
图2为革兰氏染色结果。
图3为实施例7各组样本属分类水平丰度均值结构。
图4为实施例7各疾病组菌群结构与健康组菌群结构Pearson相关系数。
具体实施方式
通过以下实施例进一步对本发明进行进一步阐述。这些实施例完全是例证性的,他们仅用来对本发明进行具体描述,不应当理解为对本发明的限制。实施例中未注明具体技术或条件者,按照本领域内的文献所描述的技术或条件,或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可通过正规渠道商购获得的常规产品。
实施例1
本实施例对从健康人体中筛选的乳酸菌进行生殖道菌群调节生长的筛选,样品的采集及保存
为评估生殖道健康女性及患有妇科疾病的生殖道菌群结构特征,采集健康女性生殖道分泌物样品15例,健康样本标准为:1月内无口服或阴道局部应用抗菌药物,无月经不调,避开月经期,无宫内置节育器,3天内存在性生活及阴道灌洗,阴道PH值≤4.5,清洁度Ⅰ-Ⅱ度。每例女性生殖道样品用无菌棉签采集三份样本,立即放入厌氧袋中,然后置入冰盒保存,及时返送实验室作后进行冻存和测序核算提取处理。其中对各例健康生殖道样品中选取1份,加入15-20%的无菌甘油,充分涡旋震荡后保存至冻存管,采用阶梯预冷法,将冻存管置于4℃预冷2小时,再置于-20℃预冻8小时,最后放置于-80℃或液氮进行保存,用于优势菌株的筛选。
实施例2
菌株的分离和筛选
为进一步获取健康生殖道菌群,用于干预紊乱状态的生殖道菌群,对健康生殖道菌群的优势菌株进行筛选。
取冻存的健康生殖道样品,梯度稀释后在MRS琼脂培养基上进行涂布培养,同一份样品平行涂布2次,分别置于厌氧、5%氧气环境中培养,培养温度均为35-37℃。
从MRS琼脂培养基上挑选单菌落菌株置于15ml MRS液体培养基,共挑选162个单菌落,并置于35-37℃摇床培养8-10h,获取发酵液。通过测发酵OD600和显微镜对比观察发酵液菌量,丢弃液体发酵效果差或无明显菌体扩增样本47份,将剩余115份发酵液各取0.5ml用于菌种测序鉴定备用,取2ml加2ml 30%-40%的甘油溶液预冷后冻存至-80℃用于备选菌种保存,剩余发酵液继续置于35-37℃摇床发酵培养每隔8h测一次pH值,连续测3次。再次发酵24h后发酵液pH最低的可达3.2。选取发酵过程中发酵液pH值下降较快、OD600较高、最终发酵pH值在3.2-3.8的样品作为备选菌种,共9个样品,编号为1号-9号。
实施例3
体外抑菌实验
鼠李糖乳杆菌GR-1和罗伊氏乳杆菌RC-14在针对生殖道菌群干预上研究成果较多且效果较好,选择作为对照菌株,与9株筛选的备选菌株一起做抑菌能力评价,分别接种在50ml MRS液体培养基中,37℃培养16h后,将发酵液10000r/min离心10min,分别收集上清液和菌体。菌体用0.9%无菌盐水洗涤两次,再用0.9%无菌盐水制备成OD600为0.5-0.8的菌悬液,4℃保存备用留存备用。
选取大肠杆菌8099、白色念珠菌ATCC10231和金黄色葡萄球菌ATCC 6538作为体外抑菌实验测试菌株,采用琼脂打孔法对各菌株的发酵上清液及菌悬液进行抑菌圈试验。用乳酸调节MRS培养液基使其与上清液PH值相同作为空白对照,浓度为0.05mg/mL的甲硝唑溶液为抑制大肠杆菌和金黄色葡萄球菌的阳性对照,浓度为0.05mg/mL的克霉唑溶液为抑制白色念珠菌的阳性对照。测量抑菌圈大小,以待测样本产生的抑菌圈半径大于MRS对照液的为有抑菌活性。除去部分抑菌效果不明显菌株,具有显著抑菌效果的菌株评价结果抑菌结果如表1所示。
表1抑菌效果评价
9号菌株的菌悬液和上清液对大肠杆菌、金黄色葡萄球菌和白色念珠菌均有显著的抑制作用,且抑菌能力优于鼠李糖乳杆菌GR-1和罗伊氏乳杆菌RC-14。
实施例4
菌株的鉴定和菌种的典藏
综合筛选菌株过程中的评价结果,既能够高产酸/耐酸,具备抑制引起妇科疾病致病菌的能力的为8号菌株,作为目标菌株。
(1)形态鉴定
取纯化菌液在显微镜下进行观察可知,细胞短,纤细或粗大,常为棒状杆菌,无分叉,菌株在MRS琼脂培养基上菌落为乳白色,呈半圆形凸起,表面光滑、湿润,边缘整齐。
(2)革兰氏染色
革兰氏染色结果为革兰氏阳性,如图2所示。
(3)16SrRNA分子生物学鉴定
利用已发表的16S通用引物(引物序列为:8F:5’-AGAFTTTGATCCTGGCTCA-3’;1510R:5’-GGTTACCTTGTTACGACTT-3’),对5号菌株的16S rDNA基因序列进行扩增和测序,PCR扩增产物送上海生工生物工程股份有限公司进行测序鉴定。5号菌株的16SrDNA的核苷酸序列为序列表中的序列1;经过16SrDNA基因比对,与Genebank中的Lactobacillus helveticus比对相似率达100%;结合微生物系统鉴定,8号菌株为一株瑞士乳杆菌,命名为瑞士乳杆菌EHA08,其16S rDNA如SEQ ID NO.1所示,生物进化树如图1所示。
对生物学鉴定的瑞士乳杆菌EHA08进行典藏,该菌株于2020年10月18日保藏于中国典型培养物保藏中心(简称CCTCC),保藏编号CCTCC NO:M2020598,保藏地址为中华人民共和国湖北省武汉市武汉大学。
实施例5
乳酸菌工业发酵及冻干粉的制备
并且便于工业扩大培养,对瑞士乳杆菌EHA08进行培养基发酵测试及冻干粉制备。
(1)培养基配置。
提供工业化高密度发酵瑞士乳杆菌EHA08培养基配置方案为:大豆蛋白胨10g/L,酵母浸粉12g/L,无水葡萄糖30g/L,磷酸氢二钾2g/L,柠檬酸氢二胺2g/L,乙酸钠5g/L,硫酸镁0.3g/L,硫酸锰0.8g/L,L-半胱胺酸盐酸盐1g/L,吐温80 1ml/L,大豆磷脂1g/L进行配置,原料均采用食品级原料进行配置。
(2)液体培养
培养基配置后调节pH值为6.5,115℃灭菌30min,冷却至38℃-39℃时,按3%-10%接种量,优选为8%进行发酵罐接种培养,培养温度为35℃-37℃,pH值为6.2-6.5,发酵过程中密封不通气体,用氮气保持发酵罐压力,慢速搅拌。连续培养8-16小时,在8h时测得发酵液活菌量为3.8×108CFU/mL,在16h时测得发酵液活菌量为2.3×1010CFU/mL,发酵活菌量水平已经较高,达到了工业化高密度发酵生产需求。
(3)离心
为避免发酵时间过长导致菌种老化,影响冻干粉菌种活性,在培养8-12小时,活菌量达到108CFU/mL-109CFU/mL,根据OD600值测得生长曲线进入平台期后快速将发酵液降温至15℃以下,使用管式离心机5000rpm进行离心,收获菌泥。
(4)保护剂乳化及冻干
收获菌泥稀释为含水量60%-80%,等体积加入菌泥保护剂进行乳化;菌泥保护剂成分为:水70%,脱脂乳粉10%,蔗糖5%,甘露糖醇5%,吐温-80 1%,甜菜碱3%,谷氨酸钠0.5%,可溶性淀粉5%。搅拌均匀后装入真空冷冻干燥机进行冷冻真空干燥,冻干物料厚度≤1cm。冻干机温度曲线为:50℃保持4h,每隔2h温度提高5℃,到第24h时温度为0℃,之后每隔2h温度提高3℃,最终最高温度为30℃保持不变,直至物料干燥,物料干燥的特点为水分含量低于5%,水活度在0.11-0.22aw。
冻干后的菌粉活性可达6.5×1011CFU/g,可便于存放。也便于用于食品添加乳酸菌粉或用于制备微生态干预制剂。
实施例6
生殖道黏膜细胞的刺激实验
依据原国家卫生部《消毒技术规范》中的阴道粘膜刺激实验标准,选用健康初成年并处在非动情期的雌性新西兰兔,试验前检查动物阴道口有无分泌物、充血、水肿和其他损伤情况。将瑞士乳杆菌EHA08冻干粉0.8g(6.5×1011CFU/g)溶于100ml无菌生理盐水作为受试液,随机选用3只雌性新西兰兔染毒,每次注入受试液2ml。对照组动物用生理盐水作同样处理。每次间隔24h,连续5天。末次染毒后24h,采用空气栓塞法处死动物,完整切下阴道后纵向切开,肉眼观察粘膜有无水肿、充血等表现,然后放入10%甲醛溶液中固定,进行组织病理学检查。
根据《消毒技术规范》中阴道粘膜侧记评分标准和刺激强度分级,瑞士乳杆菌EHA08冻干粉阴道粘膜刺激指数为0.89<1,判定为对阴道粘膜无刺激性。可以作为直接用于阴道微生态干预的生物制剂。
实施例7
微生态菌群结构的调节
选取确诊为细菌性阴道炎(BV)、HPV感染(HPV)、霉菌性阴道炎(VVC)的成年女性各5例。筛选标准为:1月内无口服或阴道局部应用抗菌药物,根据临床标准初步诊断为细菌性阴道炎、HPV感染、霉菌性阴道炎等妇科疾病。将瑞士乳杆菌EHA08冻干粉制备为片剂,其中瑞士乳杆菌EHA08冻干粉1份(活菌数为1.2×1011CFU/g),山梨糖醇8份,硬脂酸镁0.5份,微晶纤维素0.5份混合均匀后,制备0.3-1.0g/片瑞士乳杆菌EHA08冻干粉压片,在常温水中溶解时间为10-60min,作为干预生殖道菌群制剂,每日晚上1片至于阴道后穹部。选取采集的健康生殖道样本作为对照,妇科炎症患者分别在临床初步诊断选入干预组后采集生殖道样本,使用生殖道菌群制剂7天和14天再分别采集一次样本,同时跟踪记录所患妇科疾病的治愈程度,如有严重或恶化,及时有临床医生按标准临床治疗方案进行治疗。
仅使用瑞士乳杆菌EHA08冻干粉压片进行妇科疾病干预的患者中,未出现病情严重或恶化情况。15人的妇科疾病症状按照临床标准均有较好的改善,除HPV组需要继续采用抗病毒治疗,其余两组未再采用抗生素进行治疗,因此瑞士乳杆菌EHA08能够对妇科炎症进行干预治疗。
采用Illumina Miseq基因测序仪对采集的60份样品进行16S rRNA测序,获得各组样本测序数据。健康组(H)生殖道样本在门分类水平上拟杆菌门占比在89.01%-98.6%,其次放线菌门占比0.47%-3.73%,拟杆菌门占比0.14%-2.50%,软壁菌门占比0.23%-2.17%,变形菌门占比0.48%-1.06%。
各组样本的属分类水平如图3所示,图3为6个分组在属水平的均值图,图中选取了占比最高的前20个菌属,这20个菌属包含了所有样本中90%以上的菌群。可以明显看出,健康组的乳杆菌属(Lactobacillus)的含量较高,菌属含量主要集中在前5个菌属中。疾病组的乳杆菌属含量偏低,且菌属含量比例分散,结构偏复杂。也表明患有妇科疾病的生殖道菌群与健康生殖道菌群已经有明显差异,在干预7天和14天时菌群结构均有所调整,且均恢复了以乳杆菌属为主的菌群结构。
以健康组(H)为准,各疾病组菌群结构与健康组菌群结构Pearson相关系数如图4所示。从图中可以看出疾病初期的各组样本菌群结构与健康组相关性较差,在干预了7天和14天时相关系数高于0.8,说明通过瑞士乳杆菌EHA08的干预,生殖道菌群结构有较大幅度改善。
实施例8
对妇科炎症的干预及复发性
本实施例中将瑞士乳杆菌EHA08冻干粉制备成治疗妇科炎症的产品,选择62名育龄期女性参加了这项病例对照研究,其中包括15例健康对照组女性,15例细菌性阴道病患者应用甲硝唑(500mg/天,7天一疗程),17例细菌性阴道病患者应用乳杆菌活菌制剂治疗,15例治疗前的细菌性阴道病患者作为阳性对照。经过一个短期疗程的治疗后,两组治疗的患者均有80%以上获得临床治愈,其中甲硝唑治疗的BV组,有80.0%的患者获得了临床治愈(12/15),而乳杆菌活菌制剂治疗的BV组,有88.2%的患者获得了临床治愈(15/17)。治疗后,经过下一次月经周期后,再进行随访,甲硝唑治疗的BV患者组仍有4例未获得临床治愈,而只有l例患者乳杆菌活菌制剂治疗的BV患者仍未获得临床治愈。然而,此时有3例甲硝唑临床治愈的病例(3/15)在第二个随访周期复发,而乳杆菌活菌制剂临床治愈的BV患者仅有1例出现复发现象(1/17)。
实施例9
对中老年女性阴道干涩的效果
根据临床诊断标准,雌激素水平下降,症状有阴道干涩、灼热、性交痛,妇科检查为分泌物极少甚至无,阴道黏膜皱褶减少或阴道壁菲薄者为阴道干涩患者,选择阴道干涩且年龄 35-60 岁,1个月内未使用任何治疗药物,能配合完成测试患者30例,随机将患者分为治疗组和对照组各15例,治疗组给予瑞士乳杆菌EHA08冻干粉压片,对照组给予未加瑞士乳杆菌EHA08的压片,每次1片,用清水浸润后置入阴道后穹部,连续14天。其中压片配料为:瑞士乳杆菌EHA08冻干粉1份(活菌数为1.2×1011CFU/g),山梨糖醇6.9份,脂酸镁0.5份,微晶纤维素0.5份,γ-聚谷氨酸硬0.1份混合均匀后,压片机直接压制成0.5g/片的片剂。观察治疗前后阴道干涩缓解情况进行比较,结果如表2所示,根据统计结果,治疗组有较大改善,效率大86.7%。
表2中老年女性阴道干涩的疗效比较(例)
申请人声明,本发明通过上述实施例来说明本发明的详细方法,但本发明并不局限于上述详细方法,即不意味着本发明必须依赖上述详细方法才能实施。所属技术领域的技术人员应该明了,对本发明的任何改进,对本发明产品各原料的等效替换及辅助成分的添加、具体方式的选择等,均落在本发明的保护范围和公开范围之内。
序列表
<110> 南京益瑞兰生物科技有限公司
<120> 一种瑞士乳杆菌及其在制备调节生殖道微生态和缓解生殖道干涩产品中的应用
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 2800
<212> DNA
<213> 瑞士乳杆菌(Lactobacillus helveticus)
<400> 1
atacatgcaa gtcgagcgag cagaaccagc agatttactt cggtaatgac gctggggacg 60
cgagcggcgg atgggtgagt aacacgtggg gaacctgccc catagtctag gataccactt 120
ggaaacaggt gctaataccg gataataaag cagatcgcat gatcagctta taaaaggcgg 180
cgtaagctgt cgctatggga tggccccgcg gtgcattagc tagttggtaa ggtaacggct 240
taccaaggca atgatgcata gccgagttga gagactgaac ggccacattg ggactgagac 300
acggcccaaa ctcctacggg aggcagcagt agggaatctt ccacaatgga cgcaagtctg 360
atggagcaac gccgcgtgag tgaagaaggt tttcggatcg taaagctctg ttgttggtga 420
agaaggatag aggtagtaac tggcctttat ttgacggtaa tcaaccagaa agtcacggct 480
aactacgtgc cagcagccgc ggtaatacgt aggtggcaag cgttgtctgg atttattggg 540
cgtaaagcga gcgcaggcgg aagaataagt ctgatgtgaa agccctcggc ttaaccgagg 600
aattgcatcg gaaactgttt ttcttgagtg cagaagagga gagtggaact ccatgtgtag 660
cggtggaatg cgtagatata tggaagaaca ccagtggcga aggcggctct ctggtctgca 720
actgacgctg aggctcgaaa gcatgggtag cgaacaggat tagataccct ggtagtccat 780
gccgtaaacg atgagtgcta agtgttggga ggtttccgcc tctcagtgct gcagctaacg 840
cattaagcac tccgcctggg gagtacgacc gcaaggttga aactcaaagg aattgacggg 900
ggcccgcaca agcggtggag catgtggttt aattcgaagc aacgcgaaga accttaccag 960
gtcttgacat ctagtgccat cctaagagat taggagttcc cttcggggac gctaagacag 1020
gtggtgcatg gctgtcgtca gctcgtgtcg tgagatgttg ggttaagtcc cgcaacgagc 1080
gcaaccctta ttattagttg ccagcattaa gttgggcact ctaatgagac tgccggtgac 1140
aaaccggagg aaggtgggga tgacgtcaag tcatcatgcc ccttatgacc tgggctacac 1200
acgtgctaca atgggcagta caacgagaag cgagcctgcg aaggcaagcg aatctctgaa 1260
agctgttctc agttcggact gcagtctgca actcgactgc acgaagctgg aatcgctagt 1320
aatcgcggat cagaacgccg cggtgaatac gttcccgggc cttgtacaca ccgcccgtca 1380
caccatggaa gtctgcaatg cccaaagccg gtggcctaac cttcgggaag gagccgtcta 1440
aggcagggca gatgactggg gtgaagtcgt aacaaggtag ccgtaggaga acctgcggct 1500
ggatcacctc ctttctaagg aagctgaagt gatggagagt agagatacta agagaagtca 1560
caaaagcaag cggaagcaca ctgagaaact ttgtttagtt ttgagggtag tacctcaaag 1620
atttaaataa aaacaccaag cgttagtcgg gcctatagct cagctggttt agagcgcacg 1680
cctgataagc gtgaggtcga tggttcaagt ccatttaggc ccattgacat aacggctaaa 1740
aagcgataaa gttatgtctg gctgaaataa aagacttggg ggcttagctc agttgggaga 1800
gcacctgctt tgcacgcagg aggtcatcgg ttcgaacccg ttagcctcca ttgatccgaa 1860
agggtcaaag agctagtaca ttgaaaactg aatataatcc aagtaaaaaa ccgagaaaat 1920
caaagagaac agattgtaag gcgaccgaga agagaattct tgagtaaggt caagtagaaa 1980
agggcgcacg gtgaatgcct aggcactaaa agccgatgaa ggacgtgacg aactacgaaa 2040
agcttcgggg agcggtaagt acgcagtgat ccggagatgt ccgaatgggg gaacccaatg 2100
cagcgatgca ttattggttg atgaatagat agtcaatcaa aggaatacgc agtgaactga 2160
aacatctaag tagctgcagg aagagaaaga aaaatcgatt tccttagtag cggcgagcga 2220
agaggaaaga gcccaaacca agtgatttat catttggggt tgtaggactg cgacgtggca 2280
gcgtgagcga tagcagaatt atctgggaag gtaagccaga gagggtgaga gccccgtaag 2340
cgaaattgca agcgcgccta gcagaatcct gagtaggccg ggacacgaga aatcccggtt 2400
gaaaccgcga ggaccatctc gcaaggctaa atactaatta gtgaccgata gtgaaccagt 2460
accgtgaggg aaaggtgaaa agaaccccgg aaggggagtg aaatagaacc tgaaaccgtg 2520
tgtctacaag tagtcaaagc acattaaagt gcaatggcgt gccttttgta gaatgaaccg 2580
gcgagttacg ttatctagcg aggttaagtc agaaaagacg gagccggagc gaaagcgagt 2640
ctgaataggg cgagaagtta ggtgacgtag acccgaaacc aagtgaccta cccatgacca 2700
ggctgaaggc gtggtaaaac gcgctggagg gccgaaccca cgtaagttaa aaattgcggg 2760
gatgagttgt gggtagcggt gaaattccaa acgaacttgg 2800
Claims (8)
1.一种瑞士乳杆菌,其特征在于,经鉴定为瑞士乳杆菌(Lactobacillus helveticus),菌株名为EHA08,保藏于中国典型培养物保藏中心,保藏日期为2020年10月19日,保藏编号为CCTCC NO:M2020598。
2.权利要求1所述的瑞士乳杆菌在制备药物中的应用,其特征在于,所述药物用于治疗阴道炎症。
3.权利要求1所述的瑞士乳杆菌在制备药物中的应用,其特征在于,所述药物用于缓解阴道干涩。
4.根据权利要求3所述的瑞士乳杆菌在制备药物中的应用,其特征在于,所述阴道干涩为雌激素水平下降所引起的阴道干涩。
5.一种药物组合物,其特征在于,所述药物组合物包含权利要求1所述的瑞士乳杆菌。
6.根据权利要求5所述的药物组合物,其特征在于,所述药物组合物包含权利要求1所述的瑞士乳杆菌、药物载体和/或药用辅料。
7.权利要求5所述的药物组合物在制备药物中的应用,其特征在于,所述药物用于治疗阴道炎症。
8.权利要求5所述的药物组合物在制备药物中的应用,其特征在于,所述药物组合物用于缓解阴道干涩。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210649748.9A CN114717169B (zh) | 2022-06-10 | 2022-06-10 | 一种瑞士乳杆菌及其在制备调节生殖道微生态和缓解生殖道干涩产品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210649748.9A CN114717169B (zh) | 2022-06-10 | 2022-06-10 | 一种瑞士乳杆菌及其在制备调节生殖道微生态和缓解生殖道干涩产品中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114717169A CN114717169A (zh) | 2022-07-08 |
CN114717169B true CN114717169B (zh) | 2022-08-23 |
Family
ID=82232335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210649748.9A Active CN114717169B (zh) | 2022-06-10 | 2022-06-10 | 一种瑞士乳杆菌及其在制备调节生殖道微生态和缓解生殖道干涩产品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114717169B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110050987A (ko) * | 2009-11-09 | 2011-05-17 | 주식회사한국야쿠르트 | 요로감염과 칸디다성 질염을 억제하는 활성을 갖는 락토바실러스 에스피. 에이취와이7801 및 이를 유효성분으로 함유하는 제품 |
CN107998154A (zh) * | 2017-12-14 | 2018-05-08 | 广州普维君健药业有限公司 | 用于防治女性疾病的益生菌制剂及其制备方法和应用 |
CN108295096A (zh) * | 2017-12-21 | 2018-07-20 | 天津科睿恒生物科技有限公司 | 菌株在预防和治疗霉菌性、细菌性阴道炎制剂中的应用 |
CN108902981A (zh) * | 2018-04-25 | 2018-11-30 | 深圳市多微生保健食品有限公司 | 一种益生菌组合物及益生菌固体饮料 |
CN109432160A (zh) * | 2018-12-12 | 2019-03-08 | 广州普维君健药业有限公司 | 治疗女性阴道炎的益生菌组合物及其制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006045347A1 (en) * | 2004-10-22 | 2006-05-04 | Medinova Ag | Lactobacillus helveticus strain useful in the treatment or prevention of infections caused by urogenital pathogens |
-
2022
- 2022-06-10 CN CN202210649748.9A patent/CN114717169B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110050987A (ko) * | 2009-11-09 | 2011-05-17 | 주식회사한국야쿠르트 | 요로감염과 칸디다성 질염을 억제하는 활성을 갖는 락토바실러스 에스피. 에이취와이7801 및 이를 유효성분으로 함유하는 제품 |
CN107998154A (zh) * | 2017-12-14 | 2018-05-08 | 广州普维君健药业有限公司 | 用于防治女性疾病的益生菌制剂及其制备方法和应用 |
CN108295096A (zh) * | 2017-12-21 | 2018-07-20 | 天津科睿恒生物科技有限公司 | 菌株在预防和治疗霉菌性、细菌性阴道炎制剂中的应用 |
CN108902981A (zh) * | 2018-04-25 | 2018-11-30 | 深圳市多微生保健食品有限公司 | 一种益生菌组合物及益生菌固体饮料 |
CN109432160A (zh) * | 2018-12-12 | 2019-03-08 | 广州普维君健药业有限公司 | 治疗女性阴道炎的益生菌组合物及其制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
In vitro antibacterial activity of Lactobacillus helveticus strain KS300 against diarrhoeagenic, uropathogenic and vaginosis-associated bacteria;F. Atassi et al.;《Journal of Applied Microbiology》;20061231;第101卷;第647-654页 * |
Lactobacillus helveticus HY7801 ameliorates vulvovaginal candidiasis in mice by inhibiting fungal growth and NF-κB activation;Hyun-Min Joo;《International Immunopharmacology》;20121231;第14卷;第39-46页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114717169A (zh) | 2022-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110016442B (zh) | 鼠李糖乳杆菌及其复合菌粉在防治阴道炎制品中的应用 | |
TWI652343B (zh) | 一種捲曲乳桿菌(lactobacillus crispatus)及其應用 | |
WO2022100631A1 (zh) | 用于预防和/或治疗生殖道菌群紊乱相关疾病的卷曲乳杆菌 | |
JP6837015B2 (ja) | たとえば、細菌性膣炎の治療のためのLactobacillus rhamnosus(ラクトバチルス・ラムノサス)細菌 | |
TWI627276B (zh) | 新穎之卷曲乳酸桿菌(lactobacillus crispatus)菌株 | |
US11083761B2 (en) | High potency stable formulations of vaginal Lactobacillus | |
CN116200306B (zh) | 一种鼠李糖乳酪杆菌LRa16及其在制备治疗生殖道感染的药物方面的用途和产品 | |
CN116004483A (zh) | 一种预防或治疗腹泻的格氏乳球菌及其应用 | |
CN108295096B (zh) | 菌株在预防和治疗霉菌性、细菌性阴道炎制剂中的应用 | |
CN116121154B (zh) | 一种乳明串珠菌及其应用 | |
CN114774315B (zh) | 鼠李糖乳杆菌菌株LRa05在制备增强免疫力制品和/或缓解湿疹制品方面的用途 | |
CN107854495B (zh) | 凝结芽孢杆菌在制备降低血尿酸制剂中的应用 | |
CN113943681A (zh) | 一株降低炎症反应且具有缓解便秘作用的长双歧杆菌 | |
CN114717169B (zh) | 一种瑞士乳杆菌及其在制备调节生殖道微生态和缓解生殖道干涩产品中的应用 | |
US20200289585A1 (en) | Composition for competitive inhibition of pathogens and restoration of microbial ecological balance | |
CN111471623A (zh) | 三种乳杆菌的组合物及其用途 | |
CN111560335B (zh) | 一株用于缓解哮喘的乳双歧杆菌及其应用 | |
CN117327628B (zh) | 一株可发酵中草药抗HPV病毒的格氏乳杆菌Mia及其应用 | |
CN116515686B (zh) | 一株治疗女性生殖感染和调节经前心理症状的卷曲乳杆菌及其应用 | |
CN111296842A (zh) | 一种具有抗敏作用的益生菌组合物 | |
CN115137758B (zh) | 一种有利于女性生殖道健康的益生菌的制备及其应用 | |
CN110538201A (zh) | 一种乳杆菌组合物及其用途 | |
CN117264850B (zh) | 一种具有辅助治疗阴道炎和增强免疫力功能的戊糖片球菌sw006及其应用 | |
CN115433700B (zh) | 一株沙氏别样杆菌及其在制备防治炎症性肠病药物中的应用 | |
CN113924107B (zh) | 用于预防单纯性和/或复发性膀胱炎的包含酵母的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240116 Address after: Building 9, No. 99 Dingmaojing 15th Road, Zhenjiang New District, Zhenjiang City, Jiangsu Province, 212009 Patentee after: TIANYI HEALTH SCIENCE RESEARCH INSTITUTE (ZHENJIANG) Co.,Ltd. Address before: 211899 room 932, building a, phase I, Yangzi science and innovation center, No. 211, pubin Road, industrial technology research and Innovation Park, Jiangbei new area, high tech Development Zone, Nanjing, Jiangsu Province Patentee before: Nanjing yiruilan Biotechnology Co.,Ltd. |